Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tachykinin NK-1 receptor.

@article{Josien1994DesignAS,
  title={Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tachykinin NK-1 receptor.},
  author={Hubert B. Josien and Solange Lavielle and Ali{\'e} Brunissen and Monique Saffroy and Yvette Torrens and J-C. Beaujouan and Jacques Glowinski and Gérard Chassaing},
  journal={Journal of medicinal chemistry},
  year={1994},
  volume={37 11},
  pages={
          1586-601
        }
}
Constrained analogues of phenylalanine have been conceptually designed for analyzing the binding pockets of Phe7 (S7) and Phe8 (S8), two aromatic residues important for the pharmacological properties of SP, i.e., L-tetrahydroisoquinoleic acid, L-diphenylalanine, L-9-fluorenylglycine (Flg), 2-indanylglycine, the diastereomers of L-1-indanylglycine (Ing) and L-1-benz[f]indanylglycine (Bfi), and the Z and E isomers of dehydrophenylalanine (delta ZPhe, delta EPhe). Binding studies were performed… 
Topographic analysis of the S7 binding subsite of the tachykinin neurokinin-1 receptor.
TLDR
It is hypothesized that the large variations observed in the affinities of Phe7 substituted analogues of SP must come from steric hindrance in the S7 binding site, which drastically restricts the space filling around the C alpha-C beta bond of residue 7.
Analogues of arginine vasopressin and its agonist and antagonist modified in the N-terminal part of the molecule with l-beta-homophenylalanine.
TLDR
In continuation of the efforts to elucidate the role of positions 2 and 3 in arginine vasopressin (AVP) and its analogues, peptides modified in these positions with l-beta-homophenylalanine (beta-Hph) are designed and synthesized.
Further Delineation of the Two Binding Sites (R*n) Associated with Tachykinin Neurokinin-1 Receptors Using [3-Prolinomethionine11]SP Analogues*
TLDR
Newly designed constrained methionines are incorporated into the interactions between the crucial C-terminal methionine of substance P and these two binding sites to highlight the need of such constrained amino acids to probe subtle interactions in ligand-receptor complexes.
Effect of aromatic amino acid substitutions in the 3‐position of cyclic β‐casomorphin analogues on μ‐opioid agonist/δ‐opioid antagonist properties*
TLDR
Results indicate that the delta receptor tolerates bulky aromatic side chains in the 3-position of cyclic beta-casomorphin analogs with either delta agonist or delta antagonist properties, however, these compounds displayed drastically reduced mu receptor affinity in nearly all cases.
The study of the conformation and interaction of two tachykinin peptides in membrane mimicking systems by NMR spectroscopy and pulsed field gradient diffusion.
TLDR
Differences between the result of restrained molecular dynamics simulations of [Tyr(8)]SP in the presence of an explicit micelle and the present results were observed and discussed.
Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.
TLDR
New URP analogues are designed and synthesized in which the intracyclic Trp residue was replaced with natural, unnatural, and constrained amino acids to determine important physicochemical features for receptor binding and activation.
The use of photolabelled peptides to localize the substance-P-binding site in the human neurokinin-1 tachykinin receptor.
TLDR
Direct elution from the beads with the matrix used for matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS), which was facilitated by saturation of streptavidin sites with biotin, and subsequent MALDI-toF mass spectromaetry analysis allowed identification of the NK-1 fragments obtained after photolysis and proteolytic digestion.
Use of conformationally constrained peptides for a topographical analysis of the combing site of a monoclonal anti-substance P antibody.
TLDR
The present results indicate that the topography of the binding site of this monoclonal antibody differs from that of the specific substance P neurokinin-1 receptor, in agreement with the differences observed in the fine specificities of these two substance P binding macromolecules.
...
...